Abstract:Xiao Luo, 1, 2, * Zhangya He, 1, 3, * Xiaomin Sun, 1, 3 Xinqian Gu, 1, 3 Wanyu Zhang, 1, 3 Jiayi Gao, 1, 3 Xiaomin Li, 1, 3 Ru Jia, 4 Junxiang Wei, 5 Yan Yu, 1, 3 Xiaoqin Luo 1, 3 1 Department of Nutrition and Food Safety, School of Public Health, Xi'an Jiaotong University, Xi'an 710061, People's Republic of China; 2 Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an 710061, People's Republic of China; 3 Nutrition and Food Safety Engineering Research Center of Shaanxi Province, School of Medicine, Xi'an Jiaotong University, Xi'an 710061, People's Republic of China; 4 Department of Prosthodontics, Stomatological Hospital, College of Stomatology, Xi'an Jiaotong University, Xi'an 710061, People's Republic of China; 5 Department of Epidemiology and Health Statistics, School of Public Health, Xi'an Jiaotong University, Xi'an 710061, People's Republic of China *These authors contributed equally to this work Correspondence: Xiaoqin Luo Department of Nutrition and Food Safety, School of Public Health, Xi'an Jiaotong University, Xi'an 710061, People's Republic of China Tel/Fax +86-29-82655111 Email luoxiaoqin2012@mail.xjtu.edu.cn Aim: Docosahexaenoic acid (DHA; C22; n-3) shows beneficial effects on Non-alcoholic fatty liver disease (NAFLD). Deacetylase Sirtuin1 (Sirt1) was reported to increase energy metabolism and decrease lipogenesis. Here, we investigated whether DHA plays a role in protecting against hepatic steatosis via Sirt1. Main Methods: Both in vivo and in vitro hepatic steatosis models were used: diet-induced obesity (DIO) model (middle-aged C57BL/6 mice fed a high-fat diet (HFD)) and palmitic acid (PA)-induced lipid accumulation cell model (HepG2 cells). Key Findings: In DIO mice, treatment with DHA (gavage supplementation) for 8 weeks not only inhibited the lipid accumulation, but also increased fatty acids (FA) oxidation and induced triglyceride export in liver. These changes were accompanied by attenuation of inflammation. Moreover, DHA reversed the HFD-induced reduction of Sirt1 in liver. Interestingly, the beneficial effects of DHA were reversed by lentivirus-mediated Sirt1 knockdown, accompanied with increased expression of markers of lipogenesis, inflammation and reduced FA oxidation. In HepG2 cells, DHA prevented the accumulation of PA-induced lipid droplets, the decrease of FA oxidation and the reduction of Sirt1 level. Inhibition of Sirt1 by sirtinol partially reversed the beneficial effects of DHA on PA-treated cells. Significance: DHA alleviated hepatic steatosis and reduced inflammation of liver in obese middle-aged mice by mechanisms involving Sirt1 activation. Keywords: non-alcoholic fatty liver disease, steatosis, docosahexaenoic acid, high-fat diet, Sirt1

Activation of TAF9 via Danshensu-Induced Upregulation of HDAC1 Expression Alleviates Non-alcoholic Fatty Liver Disease

HADHA alleviates hepatic steatosis and oxidative stress in NAFLD via inactivation of the MKK3/MAPK pathway

Functional Proteomic Analysis of Nonalcoholic Fatty Liver Disease in Rat Models: Enoyl-coenzyme a Hydratase Down-Regulation Exacerbates Hepatic Steatosis

The DEAD-box Helicase DDX3x Ameliorates Non-Alcoholic Fatty Liver Disease Via Mtorc1 Signalling Pathway

Fatty Acids Promote Fatty Liver Disease Via the Dysregulation of 3-Mercaptopyruvate Sulfurtransferase/hydrogen Sulfide Pathway.

The Promotion of Fatty Acid Β-Oxidation by Hesperidin Via Activating SIRT1/PGC1α to Improve NAFLD Induced by a High-Fat Diet.

Cytoplasmic SIRT6-mediated ACSL5 deacetylation impedes nonalcoholic fatty liver disease by facilitating hepatic fatty acid oxidation

Hepatocyte DUSP14 Maintains Metabolic Homeostasis and Suppresses Inflammation in the Liver

Acetylation of lactate dehydrogenase B drives NAFLD progression by impairing lactate clearance

TET1 Promotes Fatty Acid Oxidation and Inhibits NAFLD Progression by Hydroxymethylation of PPARα Promoter

Quantitative proteomics of HFD-induced fatty liver uncovers novel transcription factors of lipid metabolism

DHA Protects Against Hepatic Steatosis by Activating Sirt1 in a High Fat Diet-Induced Nonalcoholic Fatty Liver Disease Mouse Model

RNA helicase DEAD‐box protein 5 alleviates nonalcoholic steatohepatitis progression via tethering TSC complex and suppressing mTORC1 signaling

Dimethyl fumarate restores Ca2+ dyshomeostasis through activation of the SIRT1 signal to treat nonalcoholic fatty liver disease

Targeting DUSP16/TAK1 Signaling Alleviates Hepatic Dyslipidemia and Inflammation in High Fat Diet (Hfd)-Challenged Mice Through Suppressing JNK MAPK.

Tripartite motif 38 alleviates the pathological process of NAFLD/NASH by promoting TAB2 degradation

Sirtuin 3‐mediated deacetylation of acyl‐ CoA synthetase family member 3 by protocatechuic acid attenuates non‐alcoholic fatty liver disease

Daphnetin Ameliorates Hepatic Steatosis by Suppressing Peroxisome Proliferator-Activated Receptor Gamma (PPARG) in Ob/ob Mice

Inhibition of Fatty Acid Translocase (FAT/CD36) Palmitoylation Enhances Hepatic Fatty Acid beta-Oxidation by Increasing Its Localization to Mitochondria and Interaction with Long-Chain Acyl-CoA Synthetase 1

Impaired SUMOylation of FoxA1 promotes nonalcoholic fatty liver disease through down-regulation of Sirt6

CSAD Ameliorates Lipid Accumulation in High-Fat Diet-Fed Mice